Conventional and high-dose daunorubicin and idarubicin in acute myeloid leukaemia remission induction treatment: a mixed treatment comparison meta-analysis of 7258 patients.

abstract：:The conventional thrombotic risk stratification in essential thrombocythemia (ET) distinguishes patients in two risk groups based on previous thrombosis and age (< or >60). The IPSET-thrombosis takes into account four risk factors: age greater than 60 years and the presence of CV risk factors, thrombosis history and J...

journal_title：Hematological oncology

authors： Santoro M,Accurso V,Mancuso S,Carlisi M,Raso S,Tarantino G,Di Piazza F,Perez A,Russo A,Siragusa S

更新日期：2019-10-01 00:00:00

abstract：:To extend the clinical-pathologic description of small cleaved cell lymphoma (SCCL), we reviewed the records of 106 patients with SCCL who were treated in accordance with a policy of watchful waiting and palliative therapy. Median age was 58 years. A pure diffuse pattern was seen in only 16 per cent of cases. Stage II...

journal_title：Hematological oncology

authors： Stein RS,Greer JP,Cousar JB,Hendey GW,Wehner JH,Flexner JM,Collins RD

更新日期：1989-09-01 00:00:00

abstract：:Recent studies have suggested that chromosomal aberrations of the MYC gene locus indicate an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL). However, there have been few reports on MYC translocation in Chinese patients. One hundred and six cases of DLBCLs were analyzed using interphase fluorescent in s...

journal_title：Hematological oncology

authors： Zhang HW,Chen ZW,Li SH,Bai W,Cheng NL,Wang JF

更新日期：2011-12-01 00:00:00

abstract：:The aim of this study was to explore the expression of retinoblastoma protein and EBV status in a cohort of cases of Hodgkin's disease from South Africa. Seventy one cases of Hodgkin's disease were accessed over a 6-year period and were classified according to the Rye Classification. Relevant sections were stained wit...

journal_title：Hematological oncology

authors： Chetty R,Bickhoo A

更新日期：1997-11-01 00:00:00

abstract：:Previous studies have shown that the incidence of non-Hodgkin's lymphoma (NHL) has increased in many parts of the world in recent decades. Using data obtained from the Canadian Cancer Registry, the present study examined time trends in NHL incidence in Canada between 1970 and 1996 and the effects of age, period of dia...

journal_title：Hematological oncology

authors： Liu S,Semenciw R,Mao Y

更新日期：2003-06-01 00:00:00

abstract：:Bone marrow (BM) is accepted as the tissue of choice for the detection of monoclonal populations in leukemias and lymphomas; however, obtaining BM can be painful and traumatic for the patients. Although it is possible to detect clonality in peripheral blood (PB) samples, there are no reports comparing the results obse...

journal_title：Hematological oncology

authors： Leal E,Esparza-Flores MA,López-Guido B,Aguilar-Luna C,Aguilar-López L,Jaloma-Cruz AR,Medina C,Barros-Núñez P

更新日期：2003-03-01 00:00:00

abstract：:The novel human pre-B cell line OZ was established from a patient with an aggressive form of non-Hodgkin's lymphoma. Karyotypic analysis of both the primary tumour and OZ cells revealed several marker chromosomes, including the t(14;18)(q32;q21) translocation, which involves the Bcl-2 gene, and alterations on chromoso...

journal_title：Hematological oncology

authors： Nagai M,Fujita M,Ohmori M,Matsubara S,Taniwaki M,Horiike S,Tasaka T,Koeffler HP,Takahara J

更新日期：1997-08-01 00:00:00

abstract：:Childhood leukemia is the commonest form of childhood cancer and represents clonal proliferation of transformed hemopoietic cells as a result of genetic changes. Molecular characterization of these changes, in particular chromosomal translocations, has yielded a wealth of information on the mechanisms of leukemogenesi...

journal_title：Hematological oncology

authors： Ma SK,Wan TS,Chan LC

更新日期：1999-09-01 00:00:00

abstract：:ABCG2 (BCRP) is a member of the ATP-binding cassette (ABC) family of cell surface transport proteins. ABCG2 expression occurs in a variety of normal tissues, and is relatively limited to primitive stem cells. ABCG2 expression is associated with the side population (SP) phenotype of Hoechst 33342 efflux. The substrate ...

journal_title：Hematological oncology

authors： Abbott BL

更新日期：2003-09-01 00:00:00

abstract：:Post-transplant lymphoproliferative disorders (PTLD) derive from antigen-experienced B-cells and represent a major complication of solid organ transplantation. We characterized usage, mutation frequency and mutation pattern of immunoglobulin variable (IGV) gene rearrangements in 50 PTLD (polymorphic PTLD, n=10; diffus...

journal_title：Hematological oncology

authors： Capello D,Cerri M,Muti G,Lucioni M,Oreste P,Gloghini A,Berra E,Deambrogi C,Franceschetti S,Rossi D,Alabiso O,Morra E,Rambaldi A,Carbone A,Paulli M,Gaidano G

更新日期：2006-12-01 00:00:00

abstract：:Thirty-seven adult patients with acute lymphoblastic leukemia were treated with a protocol called HEAV'D including Adriamycin, Vincristine, L-Asparaginase, Cyclophosphamide and Dexamethasone. The complete remission rate was 70 per cent. The median duration of remission was more than 30 months. Patients with initial le...

journal_title：Hematological oncology

authors： Barbui T,Bassan R,Chisesi T,Battista R,Cortelazzo S,Rodeghiero F,Capnist G,D'Emilio A,Viero P,Dini E

更新日期：1985-01-01 00:00:00

abstract：:This is a phase II study of panobinostat, an oral pan-HDAC inhibitor, combined with rituximab in patients with relapsed diffuse large B cell lymphoma. Panobinostat was administered orally 3 times a week every other week on a 28-day cycle. Rituximab was administered weekly during the first cycle, then on Day 1 of cycle...

journal_title：Hematological oncology

authors： Barnes JA,Redd R,Fisher DC,Hochberg EP,Takvorian T,Neuberg D,Jacobsen E,Abramson JS

更新日期：2018-10-01 00:00:00

abstract：:Left ventricular stroke distance was measured by Doppler ultrasound in 10 doxorubicin-treated and 10 control patients. Measurements were made 10 min, 2 h and 4 h after drug administration. Stroke distance (a linear analogue of stroke volume) increased significantly from 12.6 cm (S.D. 2.7) before and 12.5 cm (S.D. 2.7)...

journal_title：Hematological oncology

authors： Clive S,Dawson A,Bennett B,Rawles J

更新日期：1991-01-01 00:00:00

abstract：:The aim of the study was to describe the clinical and epidemiological characteristics, anatomic and histologic distribution, and treatment results of extranodal lymphomas (ENLs), diagnosed and treated in the public health system in Chile. We included patients with ENL diagnosed from 1998 to 2014, in 17 cancer centers,...

journal_title：Hematological oncology

authors： Peña C,Russo M,Martinez V,Cabrera ME

更新日期：2019-02-01 00:00:00

abstract：:The objective of this research was to characterize the venetoclax exposure-efficacy and exposure-safety relationships and determine its optimal dose in elderly patients with newly diagnosed acute myeloid leukemia (AML) receiving venetoclax in combination with low intensity therapies (hypomethylating agent [HMA; azacit...

journal_title：Hematological oncology

authors： Agarwal S,Gopalakrishnan S,Mensing S,Potluri J,Hayslip J,Kirschbrown W,Friedel A,Menon R,Salem AH

更新日期：2019-10-01 00:00:00

abstract：:We have treated 11 patients with relapsed or resistant lymphoma with a combination of Etoposide, Prednisolone, Ifosfamide and Carboplatin (EPIC), obtaining complete responses in two patients and partial responses in four patients for an overall response rate of 54 per cent. The treatment was well tolerated with no tox...

journal_title：Hematological oncology

authors： Richardson DS,Tighe M,Cull G,Johnson SA,Phillips MJ

更新日期：1994-05-01 00:00:00

abstract：:The relationship between myeloblast-like cells and cluster-forming cells detected by growth in agar has been studied in 22 untreated patients with acute non-lymphocytic leukemia by means of comparing data for 3H-TdR labelling of myeloblast-like cells and 3H-TdR suiciding of cluster-forming cells. The fraction of myelo...

journal_title：Hematological oncology

authors： Gustavsson A,Olofsson T,Olsson I

更新日期：1984-04-01 00:00:00

abstract：:The potential ability of antisense oligonucleotides to downregulate the expression of oncogenes involved in lymphoma, with minimal toxicity can be achieved. The possibility of combining antisense therapy such as BCL-2 antisense with chemotherapy will probably provide an interesting means of overcoming tumour cell resi...

journal_title：Hematological oncology

authors： Cotter FE

更新日期：1997-02-01 00:00:00

abstract：:Post-transplant lymphoproliferative disorders of T-cell origin are quite uncommon, and the vast majority represent neoplasms of mature, post-thymic T- or natural killer cells. Here, we report a rare case of T-cell acute lymphoblastic leukaemia (T-ALL), which occurred in an 18-year-old man who had undergone three liver...

journal_title：Hematological oncology

authors： Fang Y,Pinkney KA,Lee JC,Gindin T,Weiner MA,Alobeid B,Bhagat G

更新日期：2013-03-01 00:00:00

abstract：:Therapy with recombinant interleukin-2 (rIL-2) induces clinical response in a significant number of patients with refractory malignant disease. Very few patients with non-Hodgkin's lymphoma (NHL) have been treated with rIL-2. The present study sought to determine if peripheral blood mononuclear cells (PBM) from patien...

journal_title：Hematological oncology

authors： Zamkoff KW,Watman NP,Duggan DB,Poiesz BJ,Gottlieb AJ

更新日期：1990-03-01 00:00:00

abstract：:Implementation of cytarabine into induction therapy became standard of care for younger patients with mantle cell lymphoma (MCL). On the basis of its beneficial impact, many centers incorporated cytarabine at lower doses also into first-line treatments of elderly patients. We conducted a multicenter observational stud...

journal_title：Hematological oncology

authors： Klener P,Fronkova E,Belada D,Forsterova K,Pytlik R,Kalinova M,Simkovic M,Salek D,Mocikova H,Prochazka V,Blahovcova P,Janikova A,Markova J,Obr A,Berkova A,Kubinyi J,Vaskova M,Mejstrikova E,Campr V,Jaksa R,Kodet R,

更新日期：2018-02-01 00:00:00

abstract：:Among patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET-2) has prognostic value. However, 15% of patients with a negative PET-2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation...

journal_title：Hematological oncology

authors： Viviani S,Mazzocchi A,Pavoni C,Taverna F,Rossi A,Patti C,Romano A,Trentin L,Sorasio R,Guidetti A,Gottardi D,Tarella C,Cimminiello M,Zanotti R,Farina L,Ferreri AJM,Galbiati M,Corradini P,Gianni AM,Gallamini A,Ramba

更新日期：2020-10-01 00:00:00

abstract：:Ten patients with the myelodysplastic syndrome (eight with anemia, two with granulocytopenia, four with thrombocytopenia) were given etretinate (ER) and retinoid acid (RA). No correlation was seen between the RA effect in vitro and its clinical effect. No effect was seen of the ER-treatment or of the RA-treatment on a...

journal_title：Hematological oncology

authors： Hast R,Axdorph S,Laurén L,Reizenstein P

更新日期：1989-07-01 00:00:00

abstract：:There have been some reports on a possible role of azacytidine (AZA) in the treatment of accelerated/blastic phase evolved from Philadelphia-negative myeloproliferative neoplasms (MPN-AP/BP), but results are conflicting. In this study, we analyzed a cohort of 39 patients with MPN-AP/BP treated frontline with AZA at th...

journal_title：Hematological oncology

authors： Andriani A,Elli E,Trapè G,Villivà N,Fianchi L,Di Veroli A,Niscola P,Centra A,Anaclerico B,Montanaro G,Martini V,Aroldi A,Carmosino I,Voso MT,Breccia M,Montanaro M,Foà R,Latagliata R

更新日期：2019-08-01 00:00:00

abstract：:Multiple myeloma, which is a monoclonal plasma cell malignancy, still remains incurable despite recent progress in our understanding of this disorder. Adoptive immunotherapy of multiple myeloma using cytokine-induced killer cells is yielding promising results in clinical trials; however, some myeloma cells still evade...

journal_title：Hematological oncology

authors： Nwangwu CA,Weiher H,Schmidt-Wolf IGH

更新日期：2017-12-01 00:00:00

abstract：:The goal of current management of patients with chronic phase chronic myeloid leukemia (CML) is to reach treatment-free remission with sustained deep molecular remission (DMR) being the prerequisite therefor. Second-generation tyrosine kinase inhibitors can induce deeper and faster remission than imatinib, but are oft...

journal_title：Hematological oncology

authors： Heibl S,Buxhofer-Ausch V,Schmidt S,Webersinke G,Lion T,Piringer G,Kuehr T,Wolf D,Melchardt T,Greil R,Thaler J

更新日期：2020-12-01 00:00:00

abstract：:Given the excellent results obtained with present new induction regimens in PMBL, the role of frontline ASCT is controversial. We present 71 patients with PMBL receiving induction chemotherapy, followed by ASCT as frontline therapy from the GEL-TAMO registry. Most patients presented with high-risk clinical features. A...

journal_title：Hematological oncology

authors： Rodríguez J,Conde E,Gutiérrez A,García JC,Lahuerta JJ,Varela MR,Pérez C,Albo C,Caballero MD

更新日期：2008-09-01 00:00:00

abstract：:Delayed platelet recovery (DPR) despite prompt neutrophil engraftment is frequently observed after allogeneic hematopoietic stem cell transplantation (HSCT). However, few studies have evaluated the risk factors and long-term outcome. Therefore, we retrospectively analysed 219 adult patients who underwent their first a...

journal_title：Hematological oncology

authors： Akahoshi Y,Kimura SI,Gomyo A,Hayakawa J,Tamaki M,Harada N,Kusuda M,Kameda K,Ugai T,Wada H,Ishihara Y,Kawamura K,Sakamoto K,Sato M,Terasako-Saito K,Kikuchi M,Nakasone H,Kako S,Kanda Y

更新日期：2018-02-01 00:00:00

abstract：:Cytotoxic and DNA synthesis inhibitory effects of several iron chelators with different physicochemical properties have been tested in four myeloid leukaemic cell lines (U937, K562, ML2 and HL60). The small lipophilic chelators 8-hydroxyquinoline, tropolone and omadine at 2 X 10(-5) M, caused substantial inhibition of...

journal_title：Hematological oncology

authors： Kontoghiorghes GJ,Piga A,Hoffbrand AV

更新日期：1986-07-01 00:00:00

abstract：:Follicular lymphoma is the most common indolent non-Hodgkin lymphoma. Survival has improved over the last several decades, mainly because of the incorporation of the anti-CD20 antibody rituximab into preexisting or rediscovered agents. The disease has a relapsing and remitting pattern, coupled with a risk of transform...

journal_title：Hematological oncology

authors： Apostolidis J,Mokhtar N,Al Omari R,Darweesh M,Al Hashmi H

更新日期：2020-08-01 00:00:00